NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models.

@article{Charych2016NKTR214AE,
  title={NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models.},
  author={Deborah Charych and Ute R Hoch and John L. Langowski and Steve R. Lee and Murali K. Addepalli and Peter B Kirk and Dawei Sheng and Xiaofeng Liu and Paul W Sims and Laurie A VanderVeen and Cherie F Ali and Thomas K Chang and Marina Konakova and Rhoneil L S Pena and Rupesh S Kanhere and Yolanda M Kirksey and Chunmei Ji and Yujun Wang and Jicai Huang and Theresa D. Sweeney and Seema S Kantak and Stephen K. Doberstein},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2016},
  volume={22 3},
  pages={680-90}
}
PURPOSE Aldesleukin, recombinant human IL2, is an effective immunotherapy for metastatic melanoma and renal cancer, with durable responses in approximately 10% of patients; however, severe side effects limit maximal dosing and thus the number of patients able to receive treatment and potential cure. NKTR-214 is a prodrug of conjugated IL2, retaining the same amino acid sequence as aldesleukin. The IL2 core is conjugated to 6 releasable polyethylene glycol (PEG) chains. In vivo, the PEG chains… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 9 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 36 references

Polymers in nanomedicine

  • K Kunugi, T. Yamaoka
  • 2012

Similar Papers

Loading similar papers…